Aavogen is a biotech startup that develops gene therapeutics for muscle wasting diseases.
Aavogen has raised $350K in total funding. The most recent round was Grant. The last funding was announced in September 2025.
Aavogen's investors include National Institutes of Health, Kilpatrick Townsend & Stockton LLP, Washington Research Foundation, Convertible Note Investor.
Aavogen is headquartered in Rockville, United States.
Aavogen is a biotech startup that develops gene therapeutics for muscle wasting diseases.
Aavogen is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aavogen — Funding & Investors." VCBacked, September 5, 2025, https://www.vcbacked.co/company/aavogen. Accessed July 19, 2026.
VCBacked. (2025). Aavogen — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/aavogen
{{cite web |title=Aavogen — Funding & Investors |url=https://www.vcbacked.co/company/aavogen |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated